Actively Recruiting
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Led by Exelixis · Updated on 2026-05-14
75
Participants Needed
11
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
CONDITIONS
Official Title
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Minimum life expectancy of 65 12 weeks
- Histologically or cytologically confirmed recurrent advanced or metastatic solid tumor
- Adequate organ and marrow function
- Not eligible for curative surgery or radiation
- Received at least 1 prior systemic anticancer therapy in the recurrent or metastatic setting
- Alternative therapy was received, refused, intolerable, or no longer effective
- Able to understand and comply with study requirements and provide signed informed consent
You will not qualify if you...
- Primary brain tumors or known active brain metastases
- Major surgery within 4 weeks before first dose of study treatment
- Radiation therapy within 1 week before first dose or ongoing complications from prior radiation
- Prior therapy targeting NK cells (e.g., monalizumab)
- Positive pregnancy test within 7 days prior to study treatment for women of childbearing potential
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Exelixis Clinical Site #5
San Francisco, California, United States, 94158
Actively Recruiting
2
Exelixis Clinical Site #4
New Haven, Connecticut, United States, 06520
Actively Recruiting
3
Exelixis Clinical Site #8
Tampa, Florida, United States, 33612
Actively Recruiting
4
Exelixis Clinical Site #10
Boston, Massachusetts, United States, 02114
Actively Recruiting
5
Exelixis Clinical Site #11
Boston, Massachusetts, United States, 02114
Actively Recruiting
6
Exelixis Clinical Site #6
St Louis, Missouri, United States, 63108
Actively Recruiting
7
Exelixis Clinical Site #7
New York, New York, United States, 10029
Actively Recruiting
8
Exelixis Clinical Site #1
Hickory, North Carolina, United States, 28602
Actively Recruiting
9
Exelixis Clinical Site #3
Nashville, Tennessee, United States, 37203
Actively Recruiting
10
Exelixis Clinical Site #9
Houston, Texas, United States, 77030
Actively Recruiting
11
Exelixis Clinical Site #2
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
E
Exelixis Clinical Trials
CONTACT
B
Backup or International
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here